Background: Psoriasis can have a substantial impact on health-related quality of life (HRQoL), life course, and work productivity. Young adulthood is a critical, sensitive period of development that includes major life changing decisions. The impact of psoriasis on this vulnerable population is yet unknown.
Introduction
Psoriasis can have a substantial impact on health-related quality of life (HRQoL), encompassing individual's well-being from physical, psychological, social, occupational, and treatment perspectives (1, 2) . To date, almost 60% of patients consider psoriasis to have a major impact on their life quality (3) (4) (5) . The impact on HRQoL has even been shown to be comparable to that of depression, cardiovascular disease, and cancer (6) .
Psoriasis develops before 18 years of age in approximately one third of the adult psoriasis population, with the majority having disease onset in adolescence. The psychosocial impact of psoriasis on the young adult population (aged 18-30 years), however, is relatively unknown (7) (8) (9) .
Young adults develop their personality, plan career trajectories, establish social contacts and face major life changing decisions (MLCDs) relating to education, career choice, and social relationships (9, 10) . Accordingly, young adulthood has been postulated as a critical and sensitive period, in which psoriasis may even have a greater impact on quality of life (QoL) and ultimately on patients' life course than in older age groups (11, 12) . Kimball et al. proposed the concept of 'cumulative life course impairment' (CLCI) to indicate the cumulative effect of psoriasis and its associated comorbidities and stigma over patients' life course. CLCI results from interaction between lifelong effects of stigmatization, physical and psychological comorbidities, coping strategies, and external factors (13) . Although the exact risk factors for CLCI and their relative contribution to cumulative impairment have yet to be established, it is reasonable to state that disease onset in adolescence or young adulthood, has a greater impact on life potential than late onset psoriasis (14) . The fact that MLCDs affected by psoriasis add up to this cumulative impairment supports this hypothesis (15, 16) .
Psoriasis also has considerable economic consequences for the working-age population including young adults. Nearly half of patients regularly miss work due to their psoriasis or psoriasis treatments and work productivity is decreased compared to healthy individuals (4, 17, 18) . These effects can result in reduced socioeconomic standing and limitations in obtaining the necessary services for treatment (19) . Conversely, patients with moderate psoriasis have concerns with time and costs of psoriasis treatments, which can ultimately affect their work and insurance status (20) .
Patient-reported outcomes (PROs) are increasingly part of clinical research and daily clinical practice to understand the impact of psoriasis on QoL (21, 22) . Nonetheless, the impact of psoriasis in young adulthood is relatively unknown. This study was performed to assess QoL, life course (as determined by the achievement of developmental milestones) and work productivity in young adults with psoriasis and to explore patient and/or disease characteristics contributing to these impairments in order to provide directions for further research in this vulnerable population.
Materials and methods

Study design and population
An explorative, cross-sectional, prospective, non-interventional study was performed to assess the impact of psoriasis on HRQL in young adults. Participants were recruited between May 2014 and March 2015, from all patients with psoriasis who were seen at the outpatient clinic of the Department of Dermatology, Radboud University Medical Center. Inclusion criteria included age 18-30 years and a history of plaque psoriasis. Diagnosis was confirmed by a dermatologist. The study has been carried out in the Netherlands in accordance with the applicable rules concerning the review ethics committees and informed consent.
Data collection and management
Demographic information and psoriasis characteristics, including psoriasis severity scores (psoriasis area and severity index (PASI), body surface area (BSA), and physician global assessment (PGA)) antipsoriatic treatments received up to inclusion and the presence of comorbidities, were collected. All participants completed a set of PRO questionnaires concerning the impact of psoriasis on their life at the time of enrollment.
PRO measurements
Quality of life
To measure the impact of psoriasis on important aspects of QoL, the following questionnaires were used: dermatology life quality index (DLQI), Short Form Health Survey (SF-36), and European Quality of Life-5 Dimensions (EQ-5D).
The DLQI is a 10-question validated questionnaire that measures the degree to which a patient's life is affected by his/her skin condition over the last week (23, 24) . Total score ranges from 0 to 30; higher scores indicate greater impairment. If two or more questions are left unanswered the questionnaire is not scored. The SF-36 is a generic, 36-item, self-report health status questionnaire assessing eight domains of health status (25) . A score from 0 to 100 is calculated for each domain (Table 3) , with higher scores indicating better QoL. The SF-36 includes both cross-sectional and longitudinal components evaluating physical and psychological functioning. Different domains are summarized in a physical component score (PCS) consisting of physical functioning (PF), role physical (RP), general health (GH), and vitality (VT) scores and in and mental component score (MCS) consisting of VT, social functioning (SF), role emotional (RE), and mental health (MH). Norm-based scoring is incorporated in statistical analyses to compare PCS and MCS values to the general Dutch population norm. This population norm is set at a mean (SD) score of 50 ± 10.
The EQ-5D is another standardized generic instrument that measures five dimensions of health with three levels per dimension (26) . Total score ranges from 0 to 15; higher scores reflecting worse health state on surveyed day. The EQ-5D also includes a visual analog scale (VAS) and a Dutch population-based EQ-5D index score.
Life course: achievement of developmental milestones
The course of life questionnaire (COLQ) was used to assess the achievement of developmental milestones in our study population. This aspect has been studied in different chronic diseases but never in psoriasis. Items are divided into five scales and concern the behavior characteristics of certain stages of development, psychosocial developmental tasks and limitations children might experience when growing up with a chronic disease (27, 28) . Three out of the five scales were used in our study: (1) autonomy development, (2) psychosexual development, and (3) social development. A higher scale score indicates the accomplishment of more developmental milestones and hence a more favorable course of life.
Work productivity
The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI-PSO) instrument is a 6-item questionnaire used to assess work productivity and activity impairment related to skin psoriasis over the past week (29) . Scores are expressed in percentage of impairment (0-100). In order to estimate patients' working situation and absenteeism (work time missed) in the last three months, we included module B and C of the PROductivity and DISease Questionnaire (PRODISQ), a valid instrument to measure productivity costs (30) .
Statistical analysis
Descriptive statistics, including medians and interquartile ranges [IQR] for continuous variables and numbers and percentages (No.(%)) for categorical data, were used to explore demographic and psoriasis characteristics. Univariable relations between continuous outcome measures and possible determining factors were studied using the Mann-Whitney U test and Kruskal-Wallis H test for categorical predictors, and Spearman's rank correlation coefficients for continuous predictors. Multivariable general linear modeling was performed to further determine predicting factors for each outcome measure. Model assumptions for the generalized linear model (GLM) were reasonably met. Residuals were normally distributed and the assumption of homoscedasticity was met. p values .05 (two-sided) were considered statistically significant. The statistical package SPSS version 22.0 (IBM, Armonk, NY, USA) was used to perform all statistical analyses.
Results
Study patients
Demographic information and clinical characteristics are shown in (Table 2) . Five patients (6.7%) had psoriatic arthritis (PsA).
Quality of Life
Patients reported a median total DLQI score of 4.0 [7.0], with the impact of psoriasis interpreted as having 'no or small effect on QoL' (score 0-5) in 59.2% of our cohort and 'moderate to extreme large effect on QoL' (score 6-30) in 40.8%. Four patients left two or more questions unanswered and were therefore excluded. Highest scores were reported on the subscale 'symptoms and feelings', reflecting pain, itch and feelings of embarrassment, or self-consciousness (Table 3) . Psoriasis severity and female sex were associated with a higher total DLQI score through univariable and multivariable analysis (PGA: B ¼ 1.76; confidence interval (CI) 0.55, 2.98; p ¼ .005 and sex (female vs. male): B ¼ 2.92; 95%CI À0.04, 5.89; p ¼ .053) ( Table 4 ). In accordance with total DLQI, the DLQI subscale score 'social functioning' was also higher in females (B ¼ À12.00; 95%CI À23.32, 0.67; p ¼ .04). This score reflects the impact of psoriasis on friendships and social activities.
Patients' GH status in previous weeks was assessed by the SF-36 and EQ-5D. Median SF-36 PCS and MCS were 53.82 [7.91] and 52.32 [9. 80], respectively, just above the general population norm (31) . BMI and disease duration were negatively correlated with this PCS, indicating more physical impairment if patients suffered from higher BMI or psoriasis for a longer period. Multivariable analysis showed consistent results for disease duration (B ¼ À0.39; 95%CI 0.68, À0.09; p ¼ .012) ( Figure 1 ). Median EQ-5D VAS score, indicating patient's health status on surveyed day, was 80.00 [20.00] . Higher BMI corresponded to worse health care state in our young adult population (B ¼ À0.97; 95%CI À1.54, À0.40; p ¼ .001) ( Table 4) .
Achievement of developmental milestones
The accomplishment of certain psychosocial developmental milestones was evaluated by the COLQ. Scale scores for autonomy development, psychosocial development, and social development were respectively 9.00 [2.00], 8.00 [2.00], and 22.00 [3.00] ( Table  3) . With respect to social development, higher psoriasis severity scores and more advanced age corresponded to the achievement of fewer milestones in the social domain (e.g. contacts with peers) ( Table 4 ). Males tended to be less likely to achieve milestones of psychosexual development compared to females (e.g. relationships and sexual intimacy) (B ¼ 1.05; 95%CI 0.03, À2.07; p ¼ .045).
Work productivity
Among patients with paid work (N ¼ 51), number of working hours per week was 28.0 [28.0] . Psoriasis negatively affected work productivity in 42.2% of young adults with paid work. Mean work impairment because of reduced productivity due to psoriasis was 20.0% within the last 7 days. Limitations in the ability to do regular activities, such as studying and exercising, were reported by 59.2% of patients surveyed. Sick leave from work over the past 3 months was reported by 21.6% of patients (Table 5 ).
Discussion
The use of PRO measures to understand the impact of psoriasis on QoL has become increasingly important over the years and is essential for the development of optimal treatment strategies. However, QoL in young adults with psoriasis has received little attention so far. With approximately one third having disease onset before 18 years of age and young adulthood being a critical and sensitive period, young adults represent an important and challenging patient population (9). This study describes the impact of psoriasis on adults aged 18-30 years and to identify those who were more severely impaired and may require special attention. Approximately half of our population was classified as having minimal to mild psoriasis at enrollment (PGA score) with 38.7% receiving systemic treatment and 6.7% suffering from PsA. Almost 90% of our patients were diagnosed with psoriasis in childhood. Despite the relative stable plaque psoriasis at time of inclusion, this young adult population experienced impairments in QoL, the accomplishment of social developmental milestones, and reduced work productivity.
The observation that almost half of young adults reported a moderate to extreme large effect of psoriasis on their QoL, with highest scores on DLQI subscale 'symptoms and feelings' was comparable with previous cross-sectional studies adults with moderate to severe plaque psoriasis and palmoplantar psoriasis, and also reported in children and adolescents (32) (33) (34) . In accordance with adult psoriasis and atopic dermatitis studies, female patients and patients with more severe psoriasis seemed to do worse (35, 36) , especially in terms of self-consciousness and problems with daily activities. Characteristics that negatively affect QoL should draw our attention because of the additional vulnerability in young adulthood.
Although the overall health status measured by the SF-36 was comparable to the healthy Dutch population aged 16-40, the scores primarily reflecting the MH status (VT, GH perception, SF and MH domain) were substantially lower (31) . Again, there was a trend towards young females being more affected than their male peers with respect to SF. Overall physical health status seemed to be negatively influenced by higher BMI. Despite the described association of psoriasis with obesity in literature, it is yet unknown whether high BMI is the precursor of psoriasis or whether psoriasis leads to an increased BMI through either cytokine release and/or lifestyle (37, 38) . Subjects with relatively stable plaque psoriasis but higher BMI experienced more physical difficulties (SF-36) and worse health state (EQ-5D). Even if these difficulties are primarily the result of BMI, physical difficulties and worse health state are part of a vicious circle in psoriasis patients leading to more inactivity, aggravation of psoriasis, and ultimately CLCI. In addition, longer duration of psoriasis reduced the overall physical health status. Although the relation between age and QoL is controversial (35) , adaptation to psoriasis seemed to be more difficult for young adults with longer disease duration, at least in terms of their physical health status.
Since the cumulative effect of significant physical and psychological exposures at different time points in patient's life can produce CLCI (13, 14) , we also evaluated the achievement of developmental milestones. Even though the same milestones have been achieved with respect to autonomy, social, and psychosexual development compared to a healthy age-and sexmatched control group in a former study by Stam et al. (39) , young adults with more severe psoriasis experienced more difficulties on social development. This is in line with a study performed in young adults with atopic dermatitis, and serves as another point of concern for dermatologists in daily clinical practice (40) . Our finding that males tended to be less likely to achieve milestones of psychosexual development compared to females has not been described by others.
The observation that psoriasis negatively affected work productivity in 42.2% of our population with a productivity impairment of 20.0%, reflects the impact of psoriasis on the young working population who choose to see a dermatologist for their psoriasis at a tertiary referral center. Work deterioration was related to impairment at work (presenteeism) and missed work (absenteeism). Comparison with other working populations suffering from psoriasis or other (skin) disease is difficult because of differences in working organization between countries. Loss of productivity in 200 patients (mean age 51.4 years) with moderate to severe psoriasis enrolled in nine US sites, was estimated to be 14.2%, and highest among patients with severe psoriasis. Patients with mild psoriasis experienced only 1% impairment at work (17) . A retrospective study in 694 psoriasis patients in the USA exploring the The eight scales of the SF-36 can be aggregated into two summary measures, the PCS and MCS. The general Dutch population norm is set at a mean (SD) score of 50.0 (10.0) (32). c EuroQoL using the Dutch EQ-5D tariff. Scores reflect general health status and range from 1 (full health) to 0 (dead), and below 0 for states worse than dead. d Patients are asked to indicate his/her health status by choosing the most appropriate statement (no problems, some problems, and extreme problems) in each of the five dimensions. This statement expresses the level for that dimension on the surveyed day. Answers were dichotomized into 'having no problems' and 'having problems'. relationship between psoriasis severity and work productivity showed an overall work impairment of 7.4% in patients with mild psoriasis to 22.9% in patients suffering from severe psoriasis (18) . The fact that young adults with relatively stable psoriasis experienced more impairment at work than adult patients suffering from mild psoriasis in previous studies, supports the hypothesis of young adulthood being a critical period in which psoriasis can even have more impact on QoL and work productivity. No comparable studies have been performed in working individuals aged 18-30 years with psoriasis or other skin disease. The majority of MLCDs relating to career choice are made in young adulthood and influenced by chronic skin disease (15) . Young adults could therefore be more vulnerable to occupational disabilities due to psoriasis (33) . Our explorative, cross-sectional study was limited by the absence of a control group, introducing certain confounding bias by not eliminating external variables that can interfere with the impact on QoL. In addition, there is a potential for selection bias, as our study has been performed in a tertiary referral center. Finally, outcome measures were obtained at one moment in time. Though serial measurements would be of additional value, our study had an explorative character and aimed to provide directions for future QoL studies in the young adult psoriasis population.
In conclusion, young adults with relatively stable plaque psoriasis experienced feelings of embarrassment, impairments in daily activities, current physical health, and showed reduced productivity at work due to psoriasis. Female patients, patients with high BMI and patients with long disease duration seemed to be more severely impaired. Our findings underline the importance of the use of PRO instruments to understand problems that young adults with psoriasis meet, and emphasize the need for further prospective, case-control studies in this population to ultimately provide directions for better, patient-centered care. Physical symptoms as well as the more elusive psychosocial impact and its prognostic factors have to be clearly defined in this population and integrated into the discussion whether dermatologist should treat young adults with conventional systemics or biologics in an earlier stage of disease.
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